Jupiter Neurosciences, Inc. (JUNS)
NASDAQ: JUNS · Real-Time Price · USD
1.240
+0.130 (11.71%)
At close: Aug 13, 2025, 4:00 PM
1.224
-0.016 (-1.29%)
After-hours: Aug 13, 2025, 7:57 PM EDT
Jupiter Neurosciences Employees
Jupiter Neurosciences had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$833,598
Market Cap
41.05M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4 | 0 | - |
Dec 31, 2023 | 4 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
JUNS News
- 21 days ago - Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-Targeted Science - GlobeNewsWire
- 4 weeks ago - Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 6 weeks ago - Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery - GlobeNewsWire
- 7 weeks ago - Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador - GlobeNewsWire
- 6 months ago - Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones - GlobeNewsWire
- 6 months ago - Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson's Trial - GlobeNewsWire
- 9 months ago - Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering - GlobeNewsWire
- 9 months ago - Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq - GlobeNewsWire